Glucocorticoid-induced osteoporosis in premenopausal women: management for the rheumatologist

被引：4

作者：

Chakrabarti, Katherine ^{[1
]}

McCune, W. Joseph ^{[1
,2
]}

机构：

[1] Univ Michigan, Dept Internal Med, Div Rheumatol, Michigan, ND USA

[2] Dept Internal Med, Div Rheumatol, 300 North Ingalls St,Suite 7C27, Ann Arbor, MI 48109 USA

来源：

CURRENT OPINION IN RHEUMATOLOGY | 2023年 / 35卷 / 03期

关键词：

bisphosphonate; glucocorticoid-induced osteoporosis; premenopausal women; teratogenicity; BONE-MINERAL DENSITY; RANDOMIZED CONTROLLED-TRIAL; ALENDRONATE; BISPHOSPHONATES; FRACTURES; RISK; DENOSUMAB; DISCONTINUATION; TERIPARATIDE; METAANALYSIS;

D O I：

10.1097/BOR.0000000000000934

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Purpose of reviewThis review seeks to summarize the literature relevant to the treatment of glucocorticoid-induced osteoporosis in premenopausal women; an issue commonly encountered by rheumatologists and yet lacking good clinical practice guidelines.Recent findingsAlthough most of the relevant literature on osteoporosis includes postmenopausal women only, data from both randomized controlled trials and case reports suggest bisphosphonates can be an effective and well tolerated treatment for premenopausal patients. Data for other medications to treat premenopausal osteoporosis is less robust.The use of bisphosphonates in young women may be safer than initially thought and should likely be used for the treatment of glucocorticoid-induced osteoporosis in rheumatology clinics. Further research is needed to continue to understand long-term risk.

引用

页码：161 / 169

页数：9

共 54 条

[1] Spine Volumetric BMD and Strength in Premenopausal Idiopathic Osteoporosis: Effect of Teriparatide Followed by Denosumab [J].